Jennifer L. Guerriero

Jan 1, 2024 | nature.com | Jennifer L. Guerriero |Ziming Du |Siyang Ren |Nabihah Tayob |Shaolin Mei |Sara M. Tolaney | +1 more

AbstractEmerging data suggests that HER2 intratumoral heterogeneity (ITH) is associated with therapy resistance, highlighting the need for new strategies to assess HER2 ITH. A promising approach is leveraging multiplexed tissue analysis techniques such as cyclic immunofluorescence (CyCIF), which enable visualization and quantification of 10–60 antigens at single-cell resolution from individual tissue sections.

Dec 11, 2023 | nature.com | Carter Grochala |Jennifer L. Guerriero |Gerburg Wulf |Brian Wolpin |Ben Z. Stanger |Andrew J. Aguirre | +1 more

Retraction to: Nature Communications https://doi.org/10.1038/s41467-023-37096-6, published online 13 March 2023RETRACTION NOTEThe Editors retracted this article because of concerns regarding a number of figures presented in this work. These concerns call into question the integrity of the data and the article’s overall scientific soundness.

Jul 27, 2023 | nature.com | Jennifer L. Guerriero

Glioblastoma is an aggressive brain tumor with a highly immunosuppressive environment that responds poorly to immune checkpoint inhibitors. A study shows that SIGLEC9+ monocyte-derived macrophages are enriched in glioblastomas that do not respond to immune checkpoint inhibitors, and targeting this receptor synergizes with immunotherapy.

Mar 13, 2023 | nature.com | Jennifer L. Guerriero |Gerburg Wulf |Brian Wolpin |Ben Z. Stanger |Andrew J. Aguirre |Alan D. D’Andrea | +1 more

AbstractRecently developed inhibitors of polymerase theta (POLθ) have demonstrated synthetic lethality in BRCA-deficient tumor models. To examine the contribution of the immune microenvironment to antitumor efficacy, we characterized the effects of POLθ inhibition in immunocompetent models of BRCA1-deficient triple-negative breast cancer (TNBC) or BRCA2-deficient pancreatic ductal adenocarcinoma (PDAC).